Lowest Price Guaranteed
Pages
249
Last Updated
June 2026
View Count
13536
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of oral thin films market.
Chapter 3 provides a general introduction to the oral transmucosal route, covering details on different oral mucosal sites including the most common sublingual and buccal. The chapter also talks about the various sublingual and buccal dosage forms available in the market.
Chapter 4 provides an introduction to oral thin films, their features, advantages and disadvantages. The chapter provides details on the composition, manufacturing methods, storage and packaging of the oral thin films.
Chapter 5 highlights various developments which have taken place in the field of oral thin films. We have looked at prescription oral thin films (both marketed and in different stages of development) and some of the most common over-the-counter oral thin films. The chapter also lists the various technologies which are being used by pharmaceutical companies for developing oral thin films.
Chapter 6 provides detailed profiles on various drugs and vaccines being targeted for formulation into oral thin films. Starting with the introduction, these profiles cover historical developments of specific drugs / vaccines in other dosage forms, target population, historical sales and recent developments.
Chapter 7 looks at the future state of oral thin films market till 2025. It highlights the leading oral thin film products which are likely to drive the upcoming growth and the relative market size of oral thin films in terms of sales.
Chapter 8 provides the SWOT analysis of oral thin films market giving strategic insights to the major factors that are likely to contribute to future growth while also highlighting the weakness and threats that can negatively impact the evolution.
Chapter 9 includes profiles of the key companies active in this market. It covers detailed information on the technology provided by the each company, financial performance, marketed / pipeline products, recent developments, collaborations and future growth plans.
Chapter 10 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in the previous chapters.
Chapter 11 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.
Chapter 12 is an appendix, which provides a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. ORAL TRANSMUCOSAL DRUG DELIVERY
3.1. Chapter Overview
3.2. Oral Route
3.3. Oral Transmucosal Route
3.3.1. Sublingual Administration
3.3.2. Buccal Administration
3.3.3. Local Administration
3.4. Mechanism Involved in Oral Transmucosal Drug Administration
3.5. Advantages of Oral Transmucosal Drug administration
3.6. Disadvantages of Oral Transmucosal Drug Administration
3.7. Sublingual and Buccal Dosage Forms
3.7.1. Sublingual Tablet Forms
3.7.2. Buccal Tablet Forms
3.7.3. Sublingual and Buccal Oral Thin Films
3.7.4. Sublingual Immunotherapy (SLIT) / Sublingual Drops
3.7.5. Buccal Bioadhesive Patches
4. ORAL THIN FILMS
4.1. Chapter Overview
4.2. Emergence of Oral Thin Films
4.3. Oral Thin Films: Definition and Classification
4.3.1. Classification by Absorption Site
4.3.2. Classification by Properties / Wafer Type
4.3.3. Mechanism of Action
4.3.4. Features of an Ideal Oral Thin Film
4.3.5. Ideal Characteristics of Suitable Drug Candidates
4.4. Composition / Ingredients of Oral Thin Films
4.4.1. Active Pharmaceutical Ingredients
4.4.2. Water Soluble Polymers
4.4.3. Plasticizers
4.4.4. Saliva Stimulating Agents
4.4.5. Sweetening and Flavouring Agents
4.4.6. Surfactants and Colouring Agents
4.4.7. Permeation Enhancers
4.4.8. Stabilizing and Thickening Agents
4.5. Manufacturing Methods for Oral Thin Films
4.5.1. Solvent Casting Method
4.5.2. Semisolid Casting Method
4.5.3. Hot Melt Extrusion Method
4.5.4. Solid Dispersion Extrusion Method
4.5.5. Rolling Method
4.6. Storage and Packaging of Oral Thin Films
5. OVERVIEW AND MARKET BACKGROUND
5.1. Chapter Overview
5.2. Over-the-Counter Oral Thin Film Products
5.3. Technology and Technology Providers
5.4. Prescription Oral Thin Film Products
5.4.1. Distribution by Type of Oral Thin Film
5.4.2. Distribution by Type of Product
5.4.3. Distribution by Type of Technology
5.4.4. Distribution by Development Status
5.5. Manufacturing Facilities for Oral Thin Films
5.6. Packaging Facilities for Oral Thin Films
6. PRODUCT PROFILES
6.1. Chapter Overview
6.2. Adrenalin
6.2.1. Overview
6.2.2. Development History
6.2.3. Dosage Forms of Adrenalin
6.2.4. Target Population
6.2.5. Adrenalin Sales
6.2.6. Oral Thin Film Formulation of Adrenalin
6.2.6.1. Adrenalin Oral Transmucosal Thin Film
6.3. Apomorphine
6.3.1. Overview
6.3.2. Development History
6.3.3. Dosage Forms of Apomorphine
6.3.4. Oral Thin Film Formulation of Apomorphine
6.3.4.1. APL-130277
6.3.5. Target Population
6.3.6. Apomorphine Sales
6.4. Aripiprazole
6.4.1. Overview
6.4.2. Development History
6.4.3. Dosage Forms of Aripiprazole
6.4.4. Target Population
6.4.5. Aripiprazole Sales
6.4.6. Aripiprazole RapidFilm
6.5. Buprenorphine (Single / Combination)
6.5.1. Overview
6.5.2. Development History
6.5.3. Dosage Forms of Buprenorphine (Single / Combination)
6.5.4. Target Population
6.5.5. Oral Thin Formulation of Buprenorphine (Single / Combination)
6.5.5.1. Suboxone Film (Buprenorphine and Naloxone)
6.5.5.2. Bunavail (Buprenorphine and Naloxone)
6.5.5.3. BEMA Buprenorphine
6.5.6. Buprenorphine Sales
6.6. Donepezil
6.6.1. Overview
6.6.2. Development History
6.6.3. Dosage Forms of Donepezil
6.6.4. Target Population
6.6.5. Oral Thin Film Formulation of Donepezil
6.6.5.1. Donepezil RapidFilm
6.6.5.2. NAL8817
6.6.6. Donepezil Sales
6.7. Fentanyl
6.7.1. Overview
6.7.2. Development History
6.7.3. Dosage Forms of Fentanyl
6.7.4. Oral Thin Film Formulation of Fentanyl
6.7.4.1. Onsolis
6.7.4.2. Breakyl
6.7.4.3. Painkyl
6.7.4.4. Fastanix/ NAL1239
6.7.5. Fentanyl Sales
6.8. Flu/Influenza Vaccine
6.8.1. Overview
6.8.2. Dosage Forms of Flu/Influenza Vaccine
6.8.3. Target Population
6.8.4. Flu/Influenza Vaccine Sales
6.8.5. Oral Thin Film Formulation of Flu/Influenza Vaccine
6.9. Insulin
6.9.1. Overview
6.9.2. Dosage Forms of Insulin
6.9.3. Target Population
6.9.4. Insulin Sales
6.9.5. Oral Thin Film Formulation of Insulin
6.9.5.1. MidaForm Insulin PharmFilm
6.10. Levodopa
6.10.1. Overview
6.10.2. Development History
6.10.3. Dosage Forms of Levodopa / Carbidopa
6.10.4. Target Population
6.10.5. Levodopa/ Carbidopa Sales
6.10.6. Oral Thin Film Formulation of Levodopa
6.10.6.1. Levodopa Oral Transmucosal Thin Film
6.11. Montelukast Sodium
6.11.1. Overview
6.11.2. Development History
6.11.3. Dosage Forms of Montelukast Sodium
6.11.4. Target Population
6.11.5. Montelukast Sodium Sales
6.11.6. Oral Thin Film Formulation of Montelukast Sodium
6.11.6.1. Montelukast Sodium PharmFilm
6.11.6.2. NAL6336
6.12. Olanzapine
6.12.1. Overview
6.12.2. Development History
6.12.3. Dosage Forms of Olanzapine
6.12.4. Target Population
6.12.5. Olanzapine RapidFilm
6.12.6. Olanzapine Sales
6.13. Ondansetron
6.13.1. Overview
6.13.2. Development History
6.13.3. Target Population
6.13.4. Oral Thin Film Formulation of Ondansetron
6.13.4.1. Zuplenz
6.13.4.2. Setofilm
6.13.4.3. Ondissolve
6.13.5. Ondansetron Sales
6.14. Penicillin G
6.14.1. Overview
6.14.2. Dosage Forms of Penicillin G
6.14.3. Penicillin G Sales
6.14.4. Oral Thin Film Formulation of Penicillin G
6.14.4.1. Penicillin G Oral Transmucosal Thin Film
6.15. Rizatriptan
6.15.1. Overview
6.15.2. Development History
6.15.3. Dosage Forms of Rizatriptan
6.15.4. Target Population
6.15.5. Rizatriptan Sales
6.15.6. Oral Thin Formulation of Rizatriptan
6.15.6.1. MSRX-202
6.15.6.2. Rizaport
6.15.6.3. NAL1606
6.16. Rotavirus Vaccine
6.16.1. Overview
6.16.2. Development History
6.16.3. Dosage Forms of Rotavirus Vaccine
6.16.4. Target Population
6.16.5. Rotavirus Vaccine Sales
6.16.6. Oral Thin Film Formulation of Rotavirus Vaccine
6.16.6.1. Aridis Pharmaceuticals
6.16.6.2. Hilleman Laboratories
6.17. Testosterone
6.17.1. Overview
6.17.2. Dosage Forms of Testosterone
6.17.3. Target Population
6.17.4. Testosterone Sales
6.17.5. Oral Thin Film Formulation of Testosterone
6.17.5.1. MSRX-110
6.18. Zolmitriptan
6.18.1. Overview
6.18.2. Development History
6.18.3. Dosage Forms of Zolmitriptan
6.18.4. Target Population
6.18.5. Oral Thin Film Formulation of Zolmitriptan
6.18.5.1. Zolmitriptan RapidFilm
6.18.6. Zolmitriptan Sales
7. MARKET FORECAST
7.1. Chapter Overview
7.2. Scope and Limitations
7.3. Forecast Methodology
7.4. Overall Oral Thin Films Market, 2015-2025
7.5. Buprenorphine and Naloxone:Suboxone film (MonoSol Rx) and Bunavail (BioDelivery Sciences)
7.5.1. Suboxone film and Bunavail Sales Forecast: Short-Mid Term, 2015-2020
7.5.2. Suboxone film and Bunavail Sales Forecast: Long Term, 2020-2025
7.6. Fentanyl (BioDelivery Sciences): Onsolis (US), Breakyl (EU) and Painkyl (Canada)
7.6.1. Fentanyl Oral Thin Film Sales Forecast: Short-Mid Term, 2015-2020
7.6.2. Fentanyl Oral Thin Film Sales Forecast: Long Term, 2020-2025
7.7. Ondansetron: Zuplenz (MonoSol Rx), Setofilm (Applied Pharma Research and Labtec) and Ondissolve (Applied Pharma Research and Labtec)
7.7.1. Ondansetron Oral Thin Film Sales Forecast: Short-Mid Term, 2015-2020
7.7.2. Ondansetron Oral Thin Film Sales Forecast: Long Term, 2020-2025
7.8. Olanzapine: Olanzapine RapidFilm (Applied Pharma Research and Labtec)
7.8.1. Olanzapine RapidFilm Sales Forecast: Short-Mid Term, 2015-2020
7.8.2. Olanzapine RapidFilm Sales Forecast: Long Term, 2020-2025
7.9. Donepezil: Donepezil RapidFilm (Applied Pharma Research and Labtec)
7.9.1. Donepezil RapidFilm Sales Forecast: Short-Mid Term, 2015-2020
7.9.2. Donepezil RapidFilm Sales Forecast: Long Term, 2020-2025
7.10. Zolmitriptan: Zolmitriptan RapidFilm (Applied Pharma Research and Labtec)
7.10.1. Zolmitriptan RapidFilm Sales Forecast: Short-Mid Term, 2015-2020
7.10.2. Zolmitriptan RapidFilm Sales Forecast: Long Term, 2020-2025
7.11. Rizatriptan: Rizaport (IntelGenX)
7.11.1. Rizaport Sales Forecast: Short-Mid Term, 2016-2020
7.11.2. Rizaport Sales Forecast: Long Term, 2020-2025
7.12. Buprenorphine:BEMA Buprenorphine (BioDelivery Sciences)
7.12.1. BEMA Buprenorphine Sales Forecast: Short-Mid Term, 2016-2020
7.12.2. BEMA Buprenorphine Sales Forecast: Long Term, 2020-2025
7.13. Montelukast Sodium: Montelukast Sodium PharmFilm (MonoSol Rx)
7.13.1. Montelukast Sodium PharmFilm Sales Forecast: Short-Mid Term, 2016-2020
7.13.2. Montelukast Sodium PharmFilm Sales Forecast: Long Term, 2020-2025
8. SWOT ANALYSIS
9. COMPANY PROFILES
9.1. MonoSol Rx
9.2. tesa Labtec GmbH
9.3. IntelGenX
9.4. BioDelivery Sciences
9.5. Cynapsus Therapeutics
9.6. FFT Medical
9.7. Innoteq
9.8. Adhesives Research
10. CONCLUSION
10.1. Oral Thin Films: Significant Advantages and Major Drivers
10.2. Emergence of New Technologies
10.3. Market is Still Emerging; Launch of New Products Will Sustain the Momentum
10.4. Overall Opportunity is Big
10.5. Concluding Remarks
11. APPENDIX 1: TABULATED DATA
12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 4.1 Classification by Absorption Site
Figure 5.1 Oral Thin Films: Distribution by Type
Figure 5.2 Oral Transmucosal Thin Films: Distribution by Absorption Site
Figure 5.3 Oral Thin Films: Distribution by Type of Product
Figure 5.4 Oral Thin Films: Distribution by Type of Technology
Figure 5.5 Oral Thin Films: Distribution by Development Status
Figure 6.1 Total Adrenalin Sales (USD Million)
Figure 6.2 Total Apomorphine Hydrochloride Sales (USD Million)
Figure 6.3 Total Aripiprazole Sales (USD Million)
Figure 6.4 Total Abilify Sales (USD Million)
Figure 6.5 Historical Development of Buprenorphine (Single / Combination)
Figure 6.6 Opioid User Composition of Regions Outside the US (Million)
Figure 6.7 Total Suboxone Film Sales (USD Million)
Figure 6.8 Suboxone Film: Sales and Market Share in the US (USD Billion)
Figure 6.9 Prevalence of Alzheimer’s Disease in the US: Distribution by Age
Figure 6.10 Total Donepezil Hydrochloride Sales (USD Million)
Figure 6.11 Aricept Sales by Eisai (JPY Billion)
Figure 6.12 Aricept Sales by Pfizer (USD Million)
Figure 6.13 Total Fentanyl Sales (USD Million)
Figure 6.14 Total Fentanyl Citrate Sales (USD Million)
Figure 6.15 Total Fentanyl Transdermal System Sales (USD Million)
Figure 6.16 Total Influenza Vaccine Sales (USD Million)
Figure 6.17 Total Levodopa / Carbidopa Sales (USD Million)
Figure 6.18 Total Montelukast Sodium Sales (USD Million)
Figure 6.19 Total Singulair Sales (USD Million)
Figure 6.20 Total Olanzapine Sales (USD Million)
Figure 6.21 Total Zyprexa Sales (USD Million)
Figure 6.22 Historical Development of Ondansetron
Figure 6.23 Total Penicillin G Benzathine Sales (USD Million)
Figure 6.24 Total Penicillin G Potassium Sales (USD Million)
Figure 6.25 Total Rizatriptan Benzoate Sales (USD Million)
Figure 6.26 Total Maxalt Sales (USD Million)
Figure 6.27 Total Rotavirus Vaccine Sales (USD Million)
Figure 6.28 Total Zolmitriptan Sales (USD Million)
Figure 6.29 Total Zomig Sales (USD Million)
Figure 7.1 Overall Oral Thin Films Market (USD Million), 2015-2025 (Base Scenario)
Figure 7.2 Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.3 Suboxone film and Bunavail Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.4 Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.5 Fentanyl Oral Thin Film Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.6 Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.7 Ondansetron Oral Thin Film Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.8 Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.9 Olanzapine RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.10 Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.11 Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.12 Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Figure 7.13 Zolmitriptan RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.14 Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Figure 7.15 Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.16 BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Figure 7.17 BEMA Buprenorphine Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 7.18 Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Figure 7.19 Montelukast Sodium PharmFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Figure 9.1 IntelGenX Revenues, 2007-2013(USD Million)
Figure 9.2 BioDelivery Sciences Revenues, 2009-2013 (USD Million)
Figure 10.1 Oral Thin Films Market (USD Million): 2015, 2020, 2025
Table 4.1 Classification by Properties/Wafer Type
Table 4.2 Composition of Oral Thin Films
Table 5.1 Over-the-Counter Oral Thin Films: Marketed and Pipeline Products
Table 5.2 Oral Thin Film Technologies
Table 5.3 Prescription Oral Thin Films: Marketed and Pipeline Products
Table 5.4 Manufacturing Facilities for Oral Thin Films
Table 5.5 Companies Offering Packaging Facilities for Oral Thin Films
Table 6.1 Active Ingredients Formulated in Oral Thin Films
Table 6.2 Adrenalin Self Administering Delivery Systems
Table 6.3 Apomorphine Brand Names
Table 6.4 APL-130277 Phase II Results
Table 6.5 Abilify: Approval History
Table 6.6 Aripiprazole Dosage Forms
Table 6.7 Buprenorphine: Pharmacokinetics Characteristics
Table 6.8 Buprenorphine Dosage Forms
Table 6.9 Comparison between Buprenorphine Transmucosal Dosage Forms
Table 6.10 Brand Names of Buprenorphine (Single / Combination) Thin Films
Table 6.11 BEMA Buprenorphine: Completed Phase III Efficacy Studies
Table 6.12 Donepezil Dosage Forms
Table 6.13 Fentanyl Dosage Forms
Table 6.14 Comparison of Various Fentanyl Transmucosal Dosage Forms
Table 6.15 Oral Thin Film Fentanyl Brands
Table 6.16 Levodopa / Carbidopa Dosage Forms
Table 6.17 Montelukast Sodium Dosage Forms
Table 6.18 Olanzapine Dosage Forms
Table 6.19 Brand Names of Ondansetron Oral Thin Films
Table 6.20 Penicillin G: Derivatives and Dosage Forms
Table 6.21 Rizatriptan Dosage Forms
Table 6.22 Testosterone Dosage Forms
Table 6.23 Zolmitriptan Dosage Forms
Table 7.1 Oral Thin Film Based Products: Market Availability/Expected Launch Year
Table 8.1 SWOT Analysis
Table 8.2 Drugs that have Lost / will Lose Patent in 2014, 2015, 2016
Table 9.1 MonoSol Rx Product Portfolio
Table 9.2 Labtec Oral Dispersible Film Product Portfolio
Table 9.3 IntelGenX Product Portfolio
Table 9.4 BioDelivery Sciences Product Portfolio
Table 9.5 FFT Medical Product Portfolio
Table 11.1 Oral Thin Films: Distribution by Type
Table 11.2 Oral Transmucosal Thin Films: Distribution by Absorption Site
Table 11.3 Oral Thin Films: Distribution by Type of Product
Table 11.4 Oral Thin Films: Distribution by Type of Technology
Table 11.5 Oral Thin Films: Distribution by Development Status
Table 11.6 Total Adrenalin Sales (USD Million)
Table 11.7 Total Apomorphine Hydrochloride Sales (USD Million)
Table 11.8 Total Aripiprazole Sales (USD Million)
Table 11.9 Total Abilify Sales (USD Million)
Table 11.10 Opioid User Composition of Regions Outside the US (Million)
Table 11.11 Total Suboxone Film Sales (USD Million)
Table 11.12 Suboxone Film: Sales and Market Share in the US (USD Billion)
Table 11.13 Prevalence of Alzheimer’s Disease in the US: Distribution by Age
Table 11.14 Total Donepezil Hydrochloride Sales (USD Million)
Table 11.15 Aricept Sales by Eisai(JPY Billion)
Table 11.16 Aricept Sales by Pfizer (USD Million)
Table 11.17 Total Fentanyl Sales (USD Million)
Table 11.18 Total Fentanyl Citrate Sales (USD Million)
Table 11.19 Total Fentanyl Transdermal System Sales (USD Million)
Table 11.20 Total Influenza Vaccine Sales (USD Million)
Table 11.21 Total Levodopa / Carbidopa Sales (USD Million)
Table 11.22 Total Montelukast Sodium Sales (USD Million)
Table 11.23 Total Singulair Sales (USD Million)
Table 11.24 Total Olanzapine Sales (USD Million)
Table 11.25 Total Zyprexa Sales (USD Million)
Table 11.26 Total Penicillin G Benzathine Sales (USD Million)
Table 11.27 Total Penicillin G Potassium Sales (USD Million)
Table 11.28 Total Rizatriptan Benzoate Sales (USD Million)
Table 11.29 Total Maxalt Sales (USD Million)
Table 11.30 Total Rotavirus Vaccine Sales (USD Million)
Table 11.31 Total Zolmitriptan Sales (USD Million)
Table 11.32 Total Zomig Sales (USD Million)
Table 11.33 Overall Oral Thin Films Market (USD Million), 2015-2025 (Base Scenario)
Table 11.34 Overall Oral Thin Films Market (USD Million), 2015-2025 (Conservative Scenario)
Table 11.35 Overall Oral Thin Films Market (USD Million), 2015-2025 (Optimistic Scenario)
Table 11.36 Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.37 Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.38 Suboxone film and Bunavail Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.39 Suboxone film and Bunavail Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.40 Suboxone film and Bunavail Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
Table 11.41 Suboxone film and Bunavail Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.42 Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.43 Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.44 Fentanyl Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.45 Fentanyl Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.46 Fentanyl Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
Table 11.47 Fentanyl Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.48 Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.49 Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.50 Ondansetron Oral Thin Film Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.51 Ondansetron Oral Thin Film Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.52 Ondansetron Oral Thin Film Sales Forecast (USD Million):Long Term, 2020 -2025 (Conservative Scenario)
Table 11.53 Ondansetron Oral Thin Film Sales Forecast (USD Million): Long Term, 2020-2025 (Optimistic Scenario)
Table 11.54 Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.55 Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.56 Olanzapine RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.57 Olanzapine RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.58 Olanzapine RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
Table 11.59 Olanzapine RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.60 Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.61 Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.62 Donepezil RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.63 Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Table 11.64 Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Conservative Scenario)
Table 11.65 Donepezil RapidFilm Sales Forecast (USD Million): Long Term, 2020-2025 (Optimistic Scenario)
Table 11.66 Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Base Scenario)
Table 11.67 Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Conservative Scenario)
Table 11.68 Zolmitriptan RapidFilm Sales Forecast (USD Million): Short-Mid Term 2015-2020 (Optimistic Scenario)
Table 11.69 Zolmitriptan RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.70 Zolmitriptan RapidFilm Sales Forecast (USD Million):LongTerm, 2020-2025 (Conservative Scenario)
Table 11.71 Zolmitriptan RapidFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.72 Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Table 11.73 Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Conservative Scenario)
Table 11.74 Rizaport Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Optimistic Scenario)
Table 11.75 Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Base Scenario)
Table 11.76 Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Conservative Scenario)
Table 11.77 Rizaport Sales Forecast (USD Million): Long Term, 2020-2025 (Optimistic Scenario)
Table 11.78 BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Table 11.79 BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Conservative Scenario)
Table 11.80 BEMA Buprenorphine Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Optimistic Scenario)
Table 11.81 BEMA Buprenorphine Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.82 BEMA Buprenorphine Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
Table 11.83 BEMA Buprenorphine Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.84 Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Base Scenario)
Table 11.85 Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Conservative Scenario)
Table 11.86 Montelukast Sodium PharmFilm Sales Forecast (USD Million): Short-Mid Term 2016-2020 (Optimistic Scenario)
Table 11.87 Montelukast Sodium PharmFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Base Scenario)
Table 11.88 Montelukast Sodium PharmFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Conservative Scenario)
Table 11.89 Montelukast Sodium PharmFilm Sales Forecast (USD Million):Long Term, 2020-2025 (Optimistic Scenario)
Table 11.90 IntelGenX Revenues, 2007-2013(USD Million)
Table 11.91 BioDelivery Sciences Revenues, 2009-2013 (USD Million)
The following companies and organizations have been mentioned in the report.